NCT00361309已完成2 期
A Phase II Study of SU011248 in Advanced Hepatocellular Carcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 34
- 试验地点
- 3
- 主要终点
- Progression free survival of hepatocellular carcinoma (HCC) patients treated with SU011248.
研究概览
简要总结
The main purpose of this study is to begin to collect information and try to learn whether SU011248 works in treating patients with advanced liver cancer. Laboratory studies have shown that SU011248 may block the growth of blood vessels in tumors, which may prevent tumors from growing any further.
详细描述
- Participants will be given a supply of SU011248 capsules to be taken orally every morning for 4 weeks. After taking SU011248 for 4 weeks, there will be a 2 week rest period when the participant will not take any capsules. This 6-week period is referred to as 1 cycle.
- Participants will continue to receive SU011248 study treatment as long as their disease does not worsen significantly and they are not experiencing any serious side effects.
- During cycle 1 of study treatment, the participant will come to the outpatient clinic once a week for blood work, physical examination and dynamic contrast enhanced magnetic resonance imaging (DCE-MRI), which is done two weeks after they start taking study treatment.
- During cycle two and every cycle thereafter, the participant will be asked to come to the outpatient clinic once every two weeks for physical examination, blood work and urine tests.
- A CT scan or MRI scan to assess the tumor will be performed once during each cycle for the first three cycles, then once every 2 cycles thereafter. ACTH stimulation test will be done every 2 cycles. A MUGA scan may be done at anytime at the discretion of the the study doctor.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed HCC and should have metastatic or locally advanced unresectable disease
- •Measurable disease
- •0-1 prior systemic chemotherapy regimens for HCC
- •Age 18 years or older
- •Life expectancy of greater than 12 weeks
- •ECOG performance status of 0-1
- •Adequate organ and marrow function
- •Women of child-bearing potential must have a negative pregnancy test prior to study entry
排除标准
- •Chemotherapy, radiotherapy or major surgery within 4 weeks of study entry
- •Receiving any other investigational agents within past 30 days
- •Known brain metastases
- •CLIP score > 3
- •Chronic diarrhea or any disorder that will limit adequate absorption of SU011248
- •Prolongation of QTc > 450 msec in screening electrocardiogram or history of familial long QT syndrome
- •Uncontrolled intercurrent illness
- •Pregnant or lactating women
- •Greater than or equal to 2g of protein/24hr
研究组 & 干预措施
SU011248
Experimental
Patients will receive SU011248 37.5 mg/day for 4 weeks continuously followed by 2 weeks of rest per cycle (each cycle = 6 weeks). Patients will be continued on treatment until disease progression, limiting toxicity, or patient withdrawal of consent.
干预措施: SU011248 (Drug)
结局指标
主要结局
Progression free survival of hepatocellular carcinoma (HCC) patients treated with SU011248.
时间窗: 2 years
次要结局
- Number of adverse events in patients treated with SU011248 for advanced hepatocellular carcinoma(2 years)
- Objective Response Rate(2 years)
- Overall Survival(2 years)
研究者
Andrew X. Zhu, MD
Principal Investigator
Massachusetts General Hospital
研究点 (3)
Loading locations...
相似试验
Unknown
2 期
Sutent Maintenance After Response to TaxotereHormone RefractoryProstate CancerNCT00550810Alberta Health services30
已完成
2 期
Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney CancerKidney NeoplasmsNCT00054886Pfizer63
进行中（未招募）
不适用
A phase ii study assesing su-011248 in previously untreated patients with advanced urothelial cancer ineligible for cisplatin-based chemotherapyEstudio fase II que evalúa la eficacia y tolerabilidad de SU-011248 en pacientes previamente no tratados con cáncer uroterial no elegibles para quimioterapia basada en platinoPreviously untreated patients with advanced urothelial cancer ineligible for cisplatin-based chemotherapyEUCTR2005-005115-16-ESJoaquim Bellmunt Molins21
已完成
2 期
SU011248 for Platinum-Refractory Urothelial Cancer Evaluation TrialUrothelial CancerAdultBladder CancerNCT00578526AHS Cancer Control Alberta64
已完成
2 期
Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT00092001Pfizer111